Pharmaceutical titan AstraZeneca dropped after reporting that full-year revenue fell 15 per cent due to a loss of exclusivity on several brands. The company also said that it would not buy back any shares in 2013 "in order to maintain the flexibility to invest the business".
[31 Jan '13]Panmure Gordon has kept its 'hold' rating and 3,000p target price for pharmaceuticals giant AstraZeneca after the firm's final results, saying that figures were not as bad as they could have been.
[31 Jan '13]A host of FTSE 100 heavyweights disappointed with earnings reports on Thursday morning, as market sentiment was still fragile after yesterday's shock economic contraction in the States.
[31 Jan '13]Investec has put its 'hold' rating for Royal Dutch Shell under review after a 'substantial miss' by the oil producer in the fourth quarter.
[31 Jan '13]The FTSE 100 slumped in early trading on Thursday with heavyweight stocks AstraZeneca, Diageo, Shell and Vedanta providing a drag after disappointing the market with results.
[31 Jan '13]Royal Dutch Shell exceeded market forecasts Thursday as the oil and gas company unveiled fourth quarter and full-year results.
[31 Jan '13]The man responsible for setting boardroom pay at Barclays was hammered by MPs and peers yesterday and warned not to pay a one million-pound bonus to the new chief executive. Sir John Sunderland, one of Britain's most eminent industrialists and a for- mer CBI president, was hit by a barrage of hostile questioning and accused of a significant misjudgment in approving a 2.7 million-pound bonus to Bob Diamond, the bank's former chief, last year. He was also told that the embattle
[31 Jan '13]FTSE 100 companies are set to storm Thursday with a wave of financial results.
[30 Jan '13]